Since hospital readmission penalties in the U.S. will take effect in 2013 and mHealth technologies are expected to become more pervasive in the care delivery system, interest in remote patient monitoring is expected to remain strong especially with older adults in the coming years.
Mayo Clinic and Preventice have developed a non-invasive minimally obtrusive, interactive remote monitoring platform designed for physician-directed patient self-management and can be very useful in monitoring CHF patients.
Mayo is sponsoring a new clinical trial along with NIH as a collaborator to study the use of remote monitoring to manage cardiac patients. The clinical trial “Assessment of the BodyGuardian RMP in Elderly Healthy Subjects” (NCT01808053) is going to assess how the BodyGuardian remote health monitoring system could be improved by incorporating ECG, heart rate activity, and breathing data. Weight, blood pressure, and symptom data will also be integrated.
The study will center on individuals in an independent living center and will transmit data wireless to a central data analysis hub. The BodyGuardian sensor adheres to the patient’s skin and is smaller than a cell phone, giving patients complete mobility and freedom to go about their normal lives without restriction.
The study’s start date of March 2013 is currently recruiting 20 participants of both genders 50 years or older that are healthy with their life anticipated survival to be more than one year and living in an independent living facility.
Go to http://clinicaltrials.gov/ct2/show/NCTO1808053 for more information. The Principal Investigator is Charles J. Bruce at the Mayo Clinic. For more details, contact Nancy Lexvold at (507) 255-7013 or email email@example.com.
Another clinical trial “Patient Perspective on Remote Monitoring of Cardiovascular Implantable Electronic Devices” (NCT01691586) sponsored by UMC Ultrecht in the Netherlands is studying Remote Patient Monitoring (RPM) when the patient has a cardiovascular electronic device implanted. The study will look at how effectively RPM systems can interrogate the device automatically and then send the data from the patient’s home directly to the physician.
The purpose of the study is to evaluate the effect of RPM along with in-clinic follow-up versus in-clinic follow-up only. The second objective is to identify patients who prefer RPM over in-clinic visits and all of the cost factors involved.
The study not yet open for recruitment will include 900 individuals from 18 years old to 85 that are heart failure patients implanted with a first time ICD/CRT-D device. This study excludes patients on the waiting list for heart transplantation.
Go to http://clinicaltrials.gov/ct2/show/NCT01691586 for more information. The Principal Investigator is Mathias Maine, MD, PhD at +31 (0)88 466 6184 or email firstname.lastname@example.org. The estimated completion date is expected to be May 2016.